Preparation of substituted N-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitors
摘要:
The role of immunologically released mediators, such as histamine, leukotrienes, and platelet-activating factor, is well-established for asthma and other allergic disorders. Developing therapeutic agents which would block mediator release from mast cells and other relevant cell types would provide a rational approach to asthma therapy. Using human basophil as a screen, a series of 4-aryl-2-(phenylamino)pyrimidines was found which inhibited mediator release. These compounds were prepared by condensing acetyl heterocycles with dimethylformamide dimethyl acetal to form enaminones which are cyclized with aryl guanidines to give pyrimidines. After examining a large number of analogs, N-[3-(1H-imidazol-1-yl)phenyl]-4-(2-pyridinyl)-2-pyrimidinamine (1-27) was chosen for toxicological evaluation.
N-(3-(2-(1H-imidazol-1-yl)ethoxy)phenyl)-4-(2-thienyl)-2-pyrimidinamine and pharmacologically acceptable salts
申请人:AMERICAN CYANAMID COMPANY
公开号:EP0549880A1
公开(公告)日:1993-07-07
N-[3-[2-(1H-Imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)- 2-pyrimidinamine and pharmacologically acceptable salts, useful as antiasthma agents and treatment of allergic diseases and exhibiting improved bioavailability properties.